CN113660955A - 免疫调节性多核苷酸缀合物及其使用方法 - Google Patents
免疫调节性多核苷酸缀合物及其使用方法 Download PDFInfo
- Publication number
- CN113660955A CN113660955A CN201980082021.3A CN201980082021A CN113660955A CN 113660955 A CN113660955 A CN 113660955A CN 201980082021 A CN201980082021 A CN 201980082021A CN 113660955 A CN113660955 A CN 113660955A
- Authority
- CN
- China
- Prior art keywords
- conjugate
- integer
- group
- antibody
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747070P | 2018-10-17 | 2018-10-17 | |
| US62/747,070 | 2018-10-17 | ||
| US201862747611P | 2018-10-18 | 2018-10-18 | |
| US62/747,611 | 2018-10-18 | ||
| PCT/US2019/056619 WO2020081744A1 (en) | 2018-10-17 | 2019-10-16 | Immunomodulating polynucleotide conjugates and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113660955A true CN113660955A (zh) | 2021-11-16 |
Family
ID=70284225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980082021.3A Pending CN113660955A (zh) | 2018-10-17 | 2019-10-16 | 免疫调节性多核苷酸缀合物及其使用方法 |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| MX2024002187A (es) * | 2021-08-20 | 2024-03-12 | Tallac Therapeutics Inc | Anticuerpos y conjugados de nectina-4. |
| TW202328185A (zh) * | 2021-08-25 | 2023-07-16 | 美商泰勒克療法公司 | SIRP-α抗體及結合物 |
| WO2023081934A1 (en) * | 2021-11-08 | 2023-05-11 | The University Of Chicago | Methods and compositions for pkc-delta inhibition and cancer immunotherapy |
| KR20250039518A (ko) * | 2022-05-18 | 2025-03-20 | 탈락 테라퓨틱스, 인크. | 항-cd22 항체 올리고뉴클레오타이드 접합체를 사용하여 암을 치료하는 방법 |
| AU2025211114A1 (en) * | 2024-01-24 | 2026-06-18 | F. Hoffmann-La Roche Ag | Linkers for site-specific protein conjugation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106061981A (zh) * | 2013-11-06 | 2016-10-26 | 索尔斯蒂斯生物有限公司 | 具有二硫化物基团的多核苷酸构建体 |
| CN107109405A (zh) * | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| US20180134802A1 (en) * | 2016-01-08 | 2018-05-17 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same |
| JP2019513692A (ja) * | 2016-02-19 | 2019-05-30 | ジェニスフィア・エルエルシー | 核酸キャリア及び治療上の使用方法 |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
-
2019
- 2019-10-16 AU AU2019360216A patent/AU2019360216A1/en active Pending
- 2019-10-16 CA CA3116880A patent/CA3116880A1/en active Pending
- 2019-10-16 MX MX2021004365A patent/MX2021004365A/es unknown
- 2019-10-16 WO PCT/US2019/056619 patent/WO2020081744A1/en not_active Ceased
- 2019-10-16 CN CN201980082021.3A patent/CN113660955A/zh active Pending
- 2019-10-16 IL IL282282A patent/IL282282B2/en unknown
- 2019-10-16 SG SG11202103805SA patent/SG11202103805SA/en unknown
- 2019-10-16 US US17/283,919 patent/US20220096649A1/en not_active Abandoned
- 2019-10-16 EP EP19874575.4A patent/EP3866858A4/en active Pending
- 2019-10-16 KR KR1020217014643A patent/KR20210102204A/ko not_active Ceased
- 2019-10-16 BR BR112021007294-2A patent/BR112021007294A2/pt unknown
- 2019-10-16 JP JP2021546200A patent/JP7536025B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7536025B2 (ja) | 2024-08-19 |
| IL282282B1 (en) | 2025-03-01 |
| BR112021007294A2 (pt) | 2021-07-27 |
| IL282282A (en) | 2021-05-31 |
| JP2022508825A (ja) | 2022-01-19 |
| EP3866858A4 (en) | 2022-10-26 |
| US20220096649A1 (en) | 2022-03-31 |
| SG11202103805SA (en) | 2021-05-28 |
| IL282282B2 (en) | 2025-07-01 |
| MX2021004365A (es) | 2021-07-06 |
| AU2019360216A1 (en) | 2021-05-13 |
| CA3116880A1 (en) | 2020-04-23 |
| WO2020081744A1 (en) | 2020-04-23 |
| KR20210102204A (ko) | 2021-08-19 |
| EP3866858A1 (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7536025B2 (ja) | 免疫調節性ポリヌクレオチドコンジュゲートと使用方法 | |
| TWI913247B (zh) | 轉穀胺醯胺酶介導之結合 | |
| JP2024174865A (ja) | ヘテロ二量体四価特異性抗体およびこれらの使用 | |
| KR20220130160A (ko) | 에리불린 유도체의 약물 접합체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도 | |
| US20220025037A1 (en) | Antibody variable domains targeting dll3, and use thereof | |
| US20240228645A1 (en) | Antibodies targeting baff-r and use thereof | |
| EP3529268A1 (en) | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof | |
| TW201737941A (zh) | 新穎的b7-h3-結合分子、其抗體藥物綴合物及其使用方法 | |
| JP2017531664A (ja) | Tlr9アゴニストをチェックポイント阻害剤と共に用いるがんの治療 | |
| JP2023536627A (ja) | Egfrを標的とする抗体およびその使用 | |
| US20240382610A1 (en) | Nectin-4 antibodies and conjugates | |
| US20250340641A1 (en) | Uses of anti-icos antibodies | |
| JP2026515899A (ja) | 抗ccr8抗体、複合体、及びそれらの使用 | |
| JP7840569B2 (ja) | ヒト4-1bbアゴニスト抗体およびその使用方法 | |
| RU2830242C1 (ru) | Лекарственный конъюгат производного эрибулина, способ его получения и его применение в медицине | |
| CN117836413A (zh) | 连接蛋白-4抗体和缀合物 | |
| JP2024518843A (ja) | 抗icos抗体の使用 | |
| WO2026085393A2 (en) | T cell engager antibody-drug conjugates | |
| WO2025232773A1 (zh) | 药物组合及其用途 | |
| WO2025151406A1 (en) | Chemically modified oligonucleotides and conjugates and methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |